# Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

> clinical trial · VERIFIED · 2026-07-06

Status: ACTIVE_NOT_RECRUITING · Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Condition: Advanced Hepatocellular Carcinoma (HCC)

- Company: Shanghai Junshi Bioscience Co., Ltd.
- Sector: Advanced Hepatocellular Carcinoma (HCC)
- Primary source: https://clinicaltrials.gov/study/NCT04523493

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.